December 24, 2023
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
” data-action=subscribe>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions.
Here are some treatment approvals you may have missed in 2023.
Among important FDA treatment approvals this year were several for hospital-associated infections. Image: Adobe Stock
FDA approves Paxlovid as treatment for adults at high risk for severe COVID-19
Initially granted an emergency use authorization in December 2021, Paxlovid was granted full approval for treatment of mild-to-moderate COVID-19 based on data from three phase 2/3 trials. Read more.
FDA approves new treatment for nosocomial pneumonia
IV sulbactam-durlobactam is the “first effective, safe option” to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by drug-resistant strains of Acinetobacter baumanii-calcoaceticus complex. Read more.
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
Vowst, an oral fecal microbiome therapy, received approval in April for patients at high-risk for recurrent Clostridioides difficile infection regardless of demographics or baseline risk factors. Read more.
FDA approves new treatment for candidemia, invasive candidiasis
With the approval of the once-weekly injection Rezzzayo in March, physicians had their first new therapy in a decade for candidemia and invasive candidiasis. Read more.
Vaginal ring for HIV prevention authorized in 11 African nations
The dapivirine-releasing flexible ring has been licensed for use in 11 African nations and is available in six of them through implementation and pilot studies. With a manufacturing license awarded for local production, patients costs for the ring are expected to down. Read more.
Published by:
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
” data-action=subscribe>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
